ArticleThe Journal of clinical investigation2018

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

Kazumasa Komura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.